Introduction
Cancer is considered to be a multi-step process, occurring through an accumulation of intrinsic or extrinsic errors in responsible genes for the regulation of cell proliferation and survival. The development of human cancer can be triggered with different genes [1] . Limited abnormalities are sufficient for the development of neoplasia that is an abnormal growth of cells. The alarming increase in the cancer patients worldwide has led an unprecedented pressure on researchers to explore novel active pharmacophores with higher bioactivity, selectivity, and minimal toxicity.
PTKs are enzymes that catalyze the phosphorylation of the hydroxyl groups of tyrosine residues in various proteins by the transfer of the γ-phosphate of the ATP-Mg 2+ complex to the said amino acid side chain [2] . PTKs are key regulators of various cell functions, such as cellular growth, proliferation, migration, differentiation, and apoptosis [3] . Due to their physiological relevance, variety and ubiquity,
PTKs have become a subject of extensive study. Activation of PTKs has been shown to be critical in neoplasia progress [4] . Thus, inhibition of PTKs has become a major strategy in drug design against cancer [3] .
The Src family of kinases (SFKs) are non-receptor tyrosine kinases that are involved in signal transduction in cancer cells. c-Src is a member of SFKs which has been reported to induce STATs involved in the tumorigenesis process [5] . STAT3 is a member of signal transducer and activator of transcription protein family that regulates cell growth, survival and differentiation and has been associated with various human cancers. It has been observed that the activity of c-Src kinase in human mammary carcinomas is 4 to 20-fold greater than that in normal cells [6] . Increased Src activity elevates the cell growth rate and reduces adhesion between cells, leading to the development of metastatic potential of cells [7] [8] [9] . As a result, c-Src kinase plays an important role in the genesis and progression of human cancers, including carcinomas of the breast, colon, prostate, lung, ovary, and in myeloproliferative disorders [10] [11] [12] . Thus, the design and discovery of novel and potent c-Src kinase inhibitors remains critically important.
We have previously designed and synthesized several novel derivatives of benzopyran-2-one (coumarin) [13, 14] and benzopyran-4-one (chromone) [15] scaffold and evaluated their antiproliferative and c-Src kinase inhibitory activity. Finding new Src kinase inhibitors remains a challenging task. A more practical approach to such challenges encompasses modification of the structure of existing active pharmacophores. Pyridone skeleton has been known as an ideal frame for further exploration. Recently, myriad pyridone derivatives (Figure 1 ) have been tested for their potency against various protein kinases including Pim-1 kinase (1) [16] , Focal adhesion kinase (FAK) (2) [17] , MEK1 (3 & 4) [18, 19] , Met kinase (5, 6 & 7) [20] [21] [22] [23] and Checkpoint kinase 1 (CHK1) (8) [24] . Furthermore, 2-pyridone scaffold has been screened against Src kinases. Some 2-pyridone derivatives such as aryl aminoquinazolinepyridone (9) [25] , pyrido [2,3-d] pyrimidine (10) [26, 27] and pyridopropanamide (11) [28] have been reported as potent Src kinase inhibitors. Thus, the wealth of information for Src kinases and pyridone skeleton obtained from literature provided a strong rationale for considering inhibition of this target using pyridones to treat cancer. In the light of the above literature reports and in continuation of our efforts to explore new scaffolds as c-Src kinase inhibitors, herein, we report the synthesis and evaluation of c-Src kinase inhibitory activity of a class of novel 2-pyridone derivatives.
Results and Discussion

Chemistry
A class of novel 2-pyridone derivatives (28-45) were synthesized by reacting (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylates (23-27) with various alkylamines, N,N-dialkylaminoalkanes, and t-butyl (2-aminoethyl)carbamate in the presence of triethylamine and using ethanol as solvent (Scheme 2).
The key intermediates (20) (21) (22) , in turn were synthesized from corresponding hydroxyacetophenones by following the method reported earlier from our group [29] . In the case of dihydroxyacetophenone (13/14) , first mono-O-acetylation was carried out using acetic anhydride and pyridine while ohydroxyacetophenone (12) was used as such. 4-Oxo-4H-1-chromen-3-yl-carbaldehydes (17) (18) (19) were then synthesized using Vilsmeir-Haack formylation reaction. Since o-hydroxyacetophenone (12) and its derivatives containing various substituents takes a ring form due to H-bonding and thus prohibit enolization, therefore these compounds can be doubly formylated using Vilsmeir-Haack reagent to get 3-formyl substituted chromone derivatives [30] . The formylation reaction was followed by the Knoevenagel condensation with malonic acid to yield the respective 4-oxo-4H-chromen-3-yl)acrylic acid (20) (21) (22) (Scheme 1). When (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylates (23) (24) (25) (26) (27) were reacted with 1.1 eq. of alkyl amines, then monoalkylated products 28-43 were obtained (Scheme 2). However, by reacting ester 23 with alkylamines in the molar ratio of 1:2, dialkyl products 44-45 were obtained. Furthermore, secondary and aromatic amines e.g. morpholine, aniline, and fluoroaniline followed a different reaction pathway.
For these secondary and aromatic amines we observed the nucleophilic addition of the amine across the double bond of α, β-unsaturated ester. The addition of amine occurred at the β-carbon (C-3) due to electron withdrawing influence of the adjacent carbonyl group of acrylate 23. Thus, nucleophilic addition gave the compounds 46-48 (Scheme 2). The structure of these compounds were confirmed by their 1 (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . IC 50 is the concentration at which the enzyme activity is inhibited by 50% and is calculated from Graph Prism software. All the experiments were carried out in triplicate.
In general, among all compounds containing pyridin-2(1H)-one template, compound 36 having hydroxy and methoxy groups at meta positions on the phenyl ring and the pyridone ring linked to 2-(dimethylamino)ethyl group was found to be the most potent. Also, in continuation of our efforts to get further insights about the various 2-pyridone derivatives synthesized, the antiproliferative screening was carried out. However, the majority of compounds did not show significant antiproliferative potency compared to the positive control (Dox) at the concentration of 50 μM after 72 h incubation as shown in Figure S1 (Supporting Information). Compounds 35 and 41 exhibited noticeable inhibition potency with the proliferation of CCRF-CEM cells by 35% and 53%
respectively. Furthermore, compounds 33, 38, and 43 exhibited modest inhibitory activities in CCRF-CEM cells by 27, 27, and 26%, respectively, after 72 h incubation. However, these compounds did not exhibit a noticeable inhibition of the proliferation of SK-OV-3 and MCF-7 cells. These data indicate that there is a weak correlation between Src kinase inhibition and antiproliferative activity, presumably because of limited cellular uptake and contribution of other mechanisms in antiproliferative activity of these compounds.
Conclusion
In summary, a total of twenty one compounds including eighteen 2-pyridone derivatives and three of chromone derivatives were synthesized and fully characterized by 1 H NMR, 13 C NMR, UV, FT-IR, and high resolution mass spectroscopy (HRMS). Nineteen compounds i.e. 28-33, and 36-48 are novel.
Although compounds 34 and 35 were known in literature, their complete spectral data were not reported.
Herein, we have reported the spectral data for all of the compounds in the experimental section. All of the Structure-activity relationship of 2-pyridone derivatives for Src kinase inhibition has not been studied extensively, hence these results can be used for further optimization of 2-pyridones for designing and investigation of the potentiality of these compounds as the lead potent and selective Src kinase inhibitors.
Experimental Section
Materials and Methods
The organic solvents were dried and distilled prior to their use. Reactions were monitored by precoated 
Chemistry
General procedure for the synthesis of N-substituted pyridone derivatives (28-43)
To a solution of (4-oxo-4H-chromen-3-yl)acrylate (23-27) (4 mmol) and aminoalkane/diaminoalkane/tbutylaminoethylcarbamate (4.4 mmol) in ethanol (70 mL) was added triethylamine (2 drops), and the reaction mixture was refluxed for 8-10 h. The progress of reaction was monitored on TLC. On completion of reaction, the mixture was cooled to room temperature, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography over silica gel (100-200 mesh) in 20-40% ethyl acetate/petroleum ether to give 2-pyridone derivatives (28-43) in 74-85% yield.
1-Hexyl-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (28):
The reaction of (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylate (23) 
5-(2-Hydroxybenzoyl)-1-isopropylpyridin-2(1H)-one (29):
1-Cyclohexyl-5-(2-hydroxybenzoyl)pyridin-2(1H)-one (30):
t-Butyl [2-{5-(2,4-dihydroxybenzoyl)-2-oxopyridin-1(2H)-yl}ethyl] carbamate (33):
The reaction of (E)-ethyl 3-(7-hydroxy-4-oxo-4H-chromen-3-yl)acrylate (24) [32] : The reaction of (E)-ethyl 3-(7-methoxy-4-oxo-4H-chromen-3-yl)acrylate (26) [33] : The reaction of (E)-ethyl 3-(7-methoxy-4-oxo-4H-chromen-3-yl)acrylate (26) Hz, H-6), 11.57 ppm (brs, 1H, OH); 13 C NMR (100. 
1-Hexyl-5-(2-hydroxy-4-methoxybenzoyl)pyridin-2(1H)-one (34)
5-(2-Hydroxy-4-methoxybenzoyl)-1-isopropylpyridin-2(1H)-one (35)
1-[2-(Dimethylamino)ethyl]-5-(2-hydroxy-4-methoxybenzoyl pyridin-2(1H)-one (36):
The reaction of (E)-ethyl 3-(7-methoxy-4-oxo-4H-chromen-3-yl)acrylate (26) 
t-Butyl [2-{5-(2-hydroxy-4-methoxybenzoyl)-2-oxopyridin-1(2H)-yl}ethyl]carbamate (37):
5-(2-Hydroxy-4-methoxybenzoyl)-1-(2-hydroxyethyl)pyridin-2(1H) -one (38):
5-(2,5-Dihydroxybenzoyl)-1-hexylpyridin-2(1H)-one (39):
The reaction of (E)-ethyl 3-(6-hydroxy-4-oxo-4H-chromen-3-yl)acrylate (25) 
5-(2,5-Dihydroxybenzoyl)-1-isopropylpyridin-2(1H)-one (40):
1-Cyclohexyl-5-(2-hydroxy-5-methoxybenzoyl)pyridin-2(1H)-one (42):
The reaction of (E)- 
t-Butyl [2-{5-(2-hydroxy-5-methoxybenzoyl)-2-oxopyridin-1(2H)-yl}ethyl]carbamate (43):
The reaction of (E)-ethyl 3-(6-methoxy-4-oxo-4H-chromen-3-yl)acrylate (27) 
General Procedure for the Synthesis of N,N-dialkylimino pyridin-2(1H)-one (44-45)
To a solution of (E)-ethyl 3-(4-oxo-4H-chromen-3-yl)acrylate (23) (4 mmol) in ethanol (45 mL), primary amines (10 mmol) and few drops of triethylamine were added and stirred under reflux for about 16 h. The mixture was then cooled to room temperature, and the solvent evaporated under reduced pressure. The crude product was purified by column chromatography over silica gel using petroleum ether-ethyl acetate (15-20%) as eluent to give the desired analogues of 2-pyridone (44-45) in 75-80% yield.
(E)-5-[(2-Hydroxyphenyl)(isopropylimino)methyl]-1-isopropyl pyridin-2(1H)-one (44):
(E)-1-Cyclohexyl-5-[(cyclohexylimino)(2-hydroxyphenyl)methyl] pyridin-2(1H)-one (45):
EGFR, MAPK and PDK Inhibitory Activity Assay
The inhibitory activity of compound 36 was determined against EGFR(h) 
